Venlafaxine Hydrochloride

Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
Obstetrics and Gynecology

OBJECTIVE: To describe the effects of six interventions for menopausal vasomotor symptoms relative to control in a pooled analysis, facilitating translation of the results for clinicians and symptomatic women. The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network tested these interventions in three randomized clinical trials. METHODS: An analysis of pooled individual-level data from three randomized clinical trials is presented. Participants were 899 perimenopausal and postmenopausal women with at least 14 bothersome vasomotor symptoms per week.

Author(s): 
Guthrie, Katherine A.
LaCroix, Andrea Z.
Ensrud, Kristine E.
Joffe, Hadine
Newton, Katherine M.
Reed, Susan D.
Caan, Bette
Carpenter, Janet S.
Cohen, Lee S.
Freeman, Ellen W.
Larson, Joseph C.
Manson, JoAnn E.
Rexrode, Kathy
Skaar, Todd C.
Sternfeld, Barbara
Anderson, Garnet L.
Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Author(s): 
Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
Acta Psychiatrica Scandinavica

OBJECTIVE: To describe a never previously reported case of erotomania induced by venlafaxine and highlight the effect of antidepressants on the dopaminergic system. METHOD: A case of erotomania is described. RESULT: Erotomania occurring in two separate occasions developed after treatment with high doses of venlafaxine. The episode remitted only after lowering the dose of the venlafaxine. CONCLUSION: Erotomania may occur with agents such as antidepressants. The dopamine neurotransmission of mood can provide further evidence for the development of newer classes of antidepressants.

Author(s): 
Adamou, M.
Hale, A. S.
Subscribe to RSS - Venlafaxine Hydrochloride